# Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment

> **NCT02859103** · PHASE4 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 56 (actual)

## Conditions studied

- Depression
- Anhedonia

## Interventions

- **DRUG:** Desvenlafaxine

## Key facts

- **NCT ID:** NCT02859103
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2019-11-04
- **Final completion:** 2019-11-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859103, "Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02859103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*